Piper Sandler Maintains Overweight on Gritstone Bio, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Gritstone Bio (NASDAQ:GRTS) and raises the price target from $6 to $7.
September 28, 2023 | 11:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Gritstone Bio and raised the price target from $6 to $7, indicating a positive outlook for the company.
The raised price target by Piper Sandler indicates their belief in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100